Brokerages expect that Becton Dickinson and Co (NYSE:BDX) will report earnings of $2.92 per share for the current quarter, according to Zacks Investment Research. Nine analysts have made estimates for Becton Dickinson and’s earnings, with the highest EPS estimate coming in at $2.98 and the lowest estimate coming in at $2.89. Becton Dickinson and posted earnings per share of $2.40 in the same quarter last year, which suggests a positive year-over-year growth rate of 21.7%. The company is scheduled to report its next earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Becton Dickinson and will report full year earnings of $11.01 per share for the current year, with EPS estimates ranging from $10.99 to $11.05. For the next year, analysts expect that the firm will report earnings of $12.66 per share, with EPS estimates ranging from $12.54 to $12.75. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Becton Dickinson and.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.86 by $0.05. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. The firm had revenue of $4.28 billion for the quarter, compared to analysts’ expectations of $4.25 billion. During the same quarter last year, the company posted $2.46 earnings per share. Becton Dickinson and’s revenue was up 41.0% on a year-over-year basis.

A number of brokerages have issued reports on BDX. ValuEngine raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating in a report on Tuesday, June 26th. Wells Fargo & Co raised their target price on shares of Becton Dickinson and from $275.00 to $290.00 and gave the stock an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. JPMorgan Chase & Co. raised shares of Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 target price on the stock in a report on Thursday, June 21st. Citigroup raised their target price on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, Royal Bank of Canada reissued a “hold” rating and issued a $248.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $251.64.

Shares of NYSE BDX opened at $261.00 on Tuesday. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95. Becton Dickinson and has a 52-week low of $191.53 and a 52-week high of $263.37. The stock has a market capitalization of $69.13 billion, a price-to-earnings ratio of 24.75, a price-to-earnings-growth ratio of 1.76 and a beta of 1.10.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 28th. Stockholders of record on Friday, September 7th will be issued a dividend of $0.75 per share. The ex-dividend date is Thursday, September 6th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.15%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 31.65%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Almanack Investment Partners LLC. bought a new stake in shares of Becton Dickinson and during the second quarter valued at approximately $105,000. Bartlett & Co. LLC raised its holdings in shares of Becton Dickinson and by 2,900.0% during the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after buying an additional 435 shares during the last quarter. BDO Wealth Advisors LLC raised its holdings in shares of Becton Dickinson and by 361.6% during the first quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock valued at $125,000 after buying an additional 452 shares during the last quarter. Bridgeworth LLC bought a new stake in shares of Becton Dickinson and during the second quarter valued at approximately $131,000. Finally, Kaizen Advisory LLC raised its holdings in shares of Becton Dickinson and by 155.9% during the second quarter. Kaizen Advisory LLC now owns 609 shares of the medical instruments supplier’s stock valued at $146,000 after buying an additional 371 shares during the last quarter. 86.96% of the stock is currently owned by institutional investors.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Story: Investing in Dividend Stocks

Get a free copy of the Zacks research report on Becton Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.